Guselkumab Studied to Treat RA & Plaque Psoriasis Guselkumab (GUS) is a subcutaneously administered monoclonal antibody that targets interleukin (IL) 23.1 It is being investigated in a Phase 2 study to treat rheumatoid arthritis (RA) and moderate to severe plaque psoriasis (PsA). On June 11, 2015, at the 2015 meeting of the European League Against…
Search results for: physical function

EULAR 2015: Emerging Concepts, Treatments for Axial Spondyloarthritis
ROME, Italy—When it comes to thinking about disease modification—a main goal in the treatment of axial spondyloarthritis (axial SpA) and other inflammatory diseases—it’s time to reconsider the concept, an expert said at EULAR 2015, the annual congress of the European League Against Rheumatism (EULAR). The traditional way of assessing disease modification, inhibiting radiographic progression, is…

EULAR 2015: Innovations in Rheumatology Education, Practice
ROME, Italy—The European League Against Rheumatism (EULAR) annual congress (EULAR 2015) was a much-anticipated event, with more than 14,000 delegates attending from far and wide. The Health Professional Standing Committee was particularly delighted to have planned a program that provided the latest in research terms but also an eclectic mix of valuable topics for health…

Mindfulness May Improve Medical Efficacy in Rheumatology Patients
Every day, rheumatology patients live with the realities of having a chronic disease that requires a lifetime of treatment. This knowledge can be an emotional burden, and some people deal with it better than others. Emerging research is showing that those patients who exhibit emotional control are better able to cope and ultimately experience a…
Can We Get Closer to a Cure for RA?
Despite new therapeutics, progress for RA patients has virtually stalled over the past 10 years. In this article, the authors discuss many options to advance to a cure and the evidence for them, including the combination of low-dose methotrexate and anti-TNF; targeting angiogenesis and tissue damage pathways directly; antigen-specific therapy; potential combination of TNF and IL17 blockade; and targeting inhibitory receptors and regulatory T cells.

Biosimilar Drugs for RA Studied in Multiple Trials
Etanercept Biosimilars A number of Phase 3 trials are ongoing for etanercept biosimilars.1 One evaluation identified three trials in rheumatoid arthritis (RA) patients and one in psoriasis patients. The psoriatic arthritis trial evaluated PASI as a primary endpoint and the following secondary endpoints: PASI50, PASI75, PASI90, PASI score, laboratory values, ECG, adverse events (AEs), injection…
Knee Surgery for Pain May Not Be Worthwhile
(Reuters Health)—Middle-aged and older adults with torn cartilage or painful arthritis in their knee are not likely to benefit from arthroscopic surgery, and could be harmed by it, a review of past studies hints. Researchers reviewed nine previous studies with a combined 1,270 patients and found the surgery no better than other options like exercise…

Biosimilar Drug Updates Reported from EULAR
At the 2015 meeting of the European League Against Rheumatism in June, multiple studies were presented comparing the use of different biosimilar and biologic drugs in treating rheumatoid arthritis…
Knee Osteoarthritis Pain Worse with Insomnia
(Reuters Health)—People suffering from osteoarthritis, the most common type of joint inflammation, are more likely to have knee pain when they also have difficulty getting enough sleep, a study suggests. Researchers found that people with knee osteoarthritis and insomnia were also more likely to suffer from a nervous system disorder called “central sensitization” that makes…

Biosimilars for RA Studied in Multiple Trials
Biosimilars for etanercept and sarilumab are being examined in multiple Phase 3 trials for their effects in RA and psoriasis patients.
- « Previous Page
- 1
- …
- 18
- 19
- 20
- 21
- 22
- …
- 80
- Next Page »